How to Cite
Abstract
In recent years, the use of chemotherapeutic agents in the treatment of cancer became more common. At the same time, the number of complications associated with this is also increasing. Among the rare complications of therapy with some antitumor drugs is the formation of secondary acquired nasolacrimal duct obstruction.
The aim was to analyze and systematize information about secondary acquired nasolacrimal duct obstruction due to the toxic effect of antitumor drugs.
Materials and methods. The authors analyzed the literature available in the MEDLINE and RSCI search engines in February 2021. The analysis included 55 publications.
Results. In the literature, there are indications that such antitumor drugs as 5-fluorouracil and similar drugs, mitomycin C, as well as therapy with radioactive iodine, are characterized by the possibility of developing complications in the form of secondary acquired nasolacrimal duct obstruction. Preliminary screening of the drainage function of the tear ducts, as well as prescribing of local anti-inflammatory and antibacterial treatment in the form of instillations in the conjunctival sac can help to reduce the risk of complications. This explains the need to recommend patients to consult an ophthalmologist if there are relevant complaints before or during treatment. In the absence of timely treatment, obstruction of the tear ducts often becomes an indication for reconstructive interventions.
Conclusion. Secondary acquired nasolacrimal duct obstruction is one of the rare, but systematically occurring complications of antitumor therapy. To date, the pathogenesis of these complications is not fully understood, and some of the data is contradictory. In the future, the accumulation of knowledge concerning the pathogenesis of this complication will contribute to the development of personalized methods of prevention.
References
Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 1 // Ophthalmic Plast Reconstr Surg. 1992;8(4):237–242.
Lasudry J. The pathology of ocular syndromes caused by toxicity // Bull Soc Belge Ophtalmol. 2007;304:155–178.
Esmer O, Karadag R, Soylu E et al. Nasolacrimal system obstruction, ptosis and esotropia due to chemotherapy in acute lymphoblastic leukemia // Cutan Ocul Toxicol. 2013;32(4):330–332. doi:10.3109/15569527.2013.769560
Park J, Kim J, Baek S. Clinical features and treatment outcomes of patients with tearing after chemotherapy // Eye (Lond). 2019;33(5):746–753. doi:10.1038/s41433-018-0305-y
Stevens A, Spooner D. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer // Clin Oncol (R Coll Radiol). 2001;13(6):438–440. doi:10.1053/clon.2001.9308
Ali MJ. Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know // Ophthalmic Plast Reconstr Surg. 2016;32(4):243–248. doi:10.1097/IOP.0000000000000647
Christophidis N, Vajda FJ, Lucas I, Louis W.J. Ocular side effects with 5-fluorouracil // Aust N Z J Med. 1979;9(2):143–144. doi:10.1111/j.1445-5994.1979.tb04317.x
Esmaeli B, Ahmadi MA, Rivera E et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction // Arch Ophthalmol. 2002;120(9):1180–1182.
Fard-Esfahani A, Emami-Ardekani A, Fallahi B et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma // Nucl Med Commun. 2014;35(8):808–817. doi:10.1097/MNM.0000000000000132
Kim N, Kim JW, Baek JH et al. S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study // Cancer Res Treat. 2018;50(1):30–39. doi:10.4143/crt.2016.569
Fedorov AA, Atkova EL, Yartsev VD. Secondary Acquired Nasolacrimal Duct Obstruction as a Specific Complication of Treatment With Radioactive Iodine (Morphological Study) // Ophthalmic Plast Reconstr Surg. 2020;36(3):250–253. doi:10.1097/IOP.0000000000001521
Fraunfelder FW, Solomon J, Druker BJ et al. Ocular side-effects associated with imatinib mesylate (Gleevec) // J Ocul Pharmacol Ther. 2003;19(4):371–375. doi:10.1089/108076803322279426
Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil // Ann Intern Med. 1978;88(5):657. doi:10.7326/0003-4819-88-5-657_1
Christophidis N, Lucas I, Vajda FJ, Louis WJ. Lacrimation and 5-fluorouracil // Ann Intern Med. 1978;89(4):574. doi:10.7326/0003-4819-89-4-574_1
Eiseman AS, Flanagan JC, Brooks AB et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil // Ophthalmic Plast Reconstr Surg. 2003;19(3):216–224. doi:10.1097/01.iop.0000066648.33513.3d
Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy // Eye (Lond). 1998;12( Pt 3a):343–349. doi:10.1038/eye.1998.83
Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly // Arch Ophthalmol. 2001;119(12):1802–1804. doi:10.1001/archopht.119.12.1802
Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction // Ophthalmic Plast Reconstr Surg. 2017;33(1):9–12. doi:10.1097/IOP.0000000000000745
Fezza JP, Wesley RE, Klippenstein KA. The treatment of punctal and canalicular stenosis in patients on systemic 5-FU // Ophthalmic Surg Lasers. 1999;30(2):105–108.
Kitamura H, Miyanaga T, Shin H et al. Investigation of epiphora following S-1 therapy // Gan To Kagaku Ryoho. 2011;38(2):259–262.
Kang S, Seo JW, Sa HS. Cancer-associated epiphora: a retrospective analysis of referrals to a tertiary oculoplastic practice // Br J Ophthalmol. 2017;101(11):1566–1569. doi:10.1136/bjophthalmol-2016-309774
Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1 // Am J Ophthalmol. 2005;140(2):325–327. doi:10.1016/j.ajo.2005.01.052
Yamada R, Sotozono C, Nakamura T et al. Predictive factors for ocular complications caused by anticancer drug S-1 // Jpn J Ophthalmol. 2016;60(2):63–71. doi:10.1007/s10384-015-0421-1
Kim N, Park C, Park DJ et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy // Ann Oncol. 2012;23(8):2065–2071. doi:10.1093/annonc/mds106
Sasaki T, Miyashita H, Miyanaga T et al. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug // Jpn J Ophthalmol. 2012;56(3):214–218. doi:10.1007/s10384-012-0127-6
Noguchi Y, Mitani T, Kawara H et al. A case of lacrimal duct obstruction caused by capecitabine // Gan To Kagaku Ryoho. 2015;42(1):123–125.
Jang Y, Kim N, Lee KW et al. Nasolacrimal Duct Stenosis after Oral Capecitabine Administration // Korean J Ophthalmol. 2019;33(1):95–96. doi:10.3341/kjo.2018.0113
Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect // Ophthalmology. 2001;108(5):994–995. doi:10.1016/s0161-6420(00)00640-0
Esmaeli B. Management of excessive tearing as a side effect of docetaxel // Clin Breast Cancer. 2005;5(6):455–457. doi:10.3816/cbc.2005.n.004
Esmaeli B, Hidaji L, Adinin RB et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy // Cancer. 2003;98(3):504–507. doi:10.1002/cncr.11527
Yamagishi T, Ochi N, Yamane H et al. Epiphora in lung cancer patients receiving docetaxel: a case series // BMC Res Notes. 2014;7:322. doi:10.1186/1756-0500-7-322
Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of taxanes: The Mayo Clinic experience // Eur J Ophthalmol. 2020. doi:10.1177/1120672120969045
Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy // J Clin Oncol. 2013;31(17):2123–2127. doi:10.1200/JCO.2012.45.6574
Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora // Pharmacotherapy. 2006;26(6):853–867. doi:10.1592/phco.26.6.853
Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere) // Eye Contact Lens. 2003;29(2):134–135. doi:10.1097/01.ICL.0000062464.79558.5A
Tsalic M, Gilboa M, Visel B et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity // Med Oncol. 2006;23(1):57–61. doi:10.1385/MO:23:1:57
Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa // Ophthalmic Plast Reconstr Surg. 2003;19(4):305–308. doi:10.1097/01.IOP.0000075016.29682.E0
McCartney E, Valluri S, Rushing D, Burgett R. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel // Ophthalmic Plast Reconstr Surg. 2007;23(2):170–171. doi:10.1097/IOP.0b013e318032e908
Esmaeli B, Hortobagyi GN, Esteva FJ et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer // Ophthalmology. 2002;109(6):1188–1191. doi:10.1016/s0161-6420(02)00989-2
Tu AH, Chang EL. Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction // Ophthalmology. 2005;112(8):1469–1471. doi:10.1016/j.ophtha.2005.02.022
Sullivan TJ. Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens // Curr Opin Ophthalmol. 2012;23(5):439–442. doi:10.1097/ICU.0b013e328356ad55
Billing K, Karagiannis A, Selva D. Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia // Am J Ophthalmol. 2003;136(4):746–747. doi:10.1016/s0002-9394(03)00393-3
Kopp ED, Seregard S. Epiphora as a side effect of topical mitomycin C // Br J Ophthalmol. 2004;88(11):1422–1424. doi:10.1136/bjo.2004.048033
Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia // Br J Ophthalmol. 2006;90(7):819–822. doi:10.1136/bjo.2005.086850
Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications // Br J Ophthalmol. 2010;94(10):1316–1321. doi:10.1136/bjo.2009.176099
Goldstein DA, Tessler HH. Re: mitomycin-induced punctal stenosis // Am J Ophthalmol. 2004;137(3):593;author reply 593. doi:10.1016/j.ajo.2003.11.055
Kim KR, Song HY, Shin JH et al. Efficacy of mitomycin-C irrigation after balloon dacryocystoplasty // J Vasc Interv Radiol. 2007;18(6):757–762. doi:10.1016/j.jvir.2007.04.001
Atkova EL, Fedorov AA, Root AO et al. Causes of unsatisfactory results of the use of mitomycin-C in endoscopic endonasal dacryocystorhinostomy // Saudi J Ophthalmol. 2017;31(3):150–155. doi:10.1016/j.sjopt.2017.05.007
Щербаков Д.А., Попов И.Б., Кротова А.С. и др. Трансканаликулярная ирригация митомицином С при повторной эндоскопической эндоназальной дакриоцисториностомии // Отражение. 2018;1(6):208–210.
Yartsev VD, Solodkiy VA, Fomin DK et al. Clinical and Demographic Characteristics of Tearing in Patients after Radioiodine Ablation for Differentiated Thyroid Cancer // Curr Eye Res. 2021:1–5. doi:10.1080/02713683.2021.1878229
Fard-Esfahani A, Farzanefar S, Fallahi B et al. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer // Nucl Med Commun. 2012;33(10):1077–1080. doi:10.1097/MNM.0b013e3283570fb8
Ярцев В.Д., Атькова Е.Л. Вторичная облитерация слезоотводящих путей после терапии радиоактивным йодом // Проблемы эндокринологии. 2018;64(6):397–401. doi:0.14341/probl9716
da Fonseca FL, Yamanaka PK, Kato JM, Matayoshi S. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study // Thyroid. 2016;26(12):1761–1767. doi:10.1089/thy.2015.0657
Белдовская Н.Ю., Карпищенко С.А., Баранская С.В., Карпов А.А. Патология слёзных органов у пациентов со злокачественными опухолями щитовидной железы после терапии радиоактивным йодом и методы её коррекции // Офтальмологические ведомости. 2017;10(4):13–17. doi:10.17816/OV10413-17
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021